Log In
Print this Print this


  Manage Alerts
Collapse Summary General Information
Company Johnson & Johnson
DescriptionBispecific antibody that targets CD3 and IL-3 receptor alpha (CD123)
Molecular Target CD3 ; Interleukin-3 (IL-3) receptor alpha (CD123)
Mechanism of ActionAntibody
Therapeutic ModalityBiologic: Antibody
Latest Stage of DevelopmentPhase I
Standard IndicationAcute myelogenous leukemia (AML)
Indication DetailsTreat acute myelogenous leukemia (AML)
Regulatory Designation
PartnerGenmab A/S

 Product Details
 Archive Items are loading loading
Collapse Summary Deals Information
 Deals Details
Get a free BioCentury trial today